199 related articles for article (PubMed ID: 28779162)
1. A time-resolved fluoroimmunoassay to assay the rabies virus glycoprotein: application for estimation of human rabies vaccine potency.
Lin G; Chen S; Zhao H; Liang J; Deng Q; Liang R; Guo X; Chen Z; Chen B; Liu T; Wu Y
Sci Rep; 2017 Aug; 7(1):7288. PubMed ID: 28779162
[TBL] [Abstract][Full Text] [Related]
2. A time-resolved fluoroimmunoassay for assessing rabies antibody titers in the sera of vaccinated human subjects.
Bian L; Zhao H; He C; Fang H; Chen Z; Lin L; Ye K; Wu Y; Lin G
Biologicals; 2020 Nov; 68():54-59. PubMed ID: 32868168
[TBL] [Abstract][Full Text] [Related]
3. Development of competitive inhibition ELISA as an effective potency test to analyze human rabies vaccines and assessment of the antigenic epitope of rabies glycoprotein.
Soni D; Sahoo I; Mallya AD; Kamthe P; Sahai A; Goel SK; Kulkarni PS; Dhere RM
J Immunol Methods; 2021 May; 492():112939. PubMed ID: 33309752
[TBL] [Abstract][Full Text] [Related]
4. G-protein based ELISA as a potency test for rabies vaccines.
Chabaud-Riou M; Moreno N; Guinchard F; Nicolai MC; Niogret-Siohan E; Sève N; Manin C; Guinet-Morlot F; Riou P
Biologicals; 2017 Mar; 46():124-129. PubMed ID: 28214171
[TBL] [Abstract][Full Text] [Related]
5. In Vitro ELISA Test to Evaluate Rabies Vaccine Potency.
Jallet C; Tordo N
J Vis Exp; 2020 May; (159):. PubMed ID: 32449742
[TBL] [Abstract][Full Text] [Related]
6. A time-resolved fluoroimmunoassay for the quantitation of rabies virus nucleoprotein in the rabies vaccine.
Lin G; Huang H; Liu T; He C; Liu J; Chen S; Hou J; Ren Z; Dong W; Wu Y
J Virol Methods; 2014 Sep; 206():89-94. PubMed ID: 24928690
[TBL] [Abstract][Full Text] [Related]
7. In vitro rabies vaccine potency appraisal by ELISA: advantages of the immunocapture method with a neutralizing anti-glycoprotein monoclonal antibody.
Perrin P; Morgeaux S; Sureau P
Biologicals; 1990 Oct; 18(4):321-30. PubMed ID: 2285504
[TBL] [Abstract][Full Text] [Related]
8. Verification of the rabies virus glycoprotein lower limit of immunogenicity by serological assay.
Moreira WC; Machado NS; Freitas JFS; Almeida AECC; Moura WC
J Virol Methods; 2019 Feb; 264():31-37. PubMed ID: 30448319
[TBL] [Abstract][Full Text] [Related]
9. A relevant in vitro ELISA test in alternative to the in vivo NIH test for human rabies vaccine batch release.
Gibert R; Alberti M; Poirier B; Jallet C; Tordo N; Morgeaux S
Vaccine; 2013 Dec; 31(50):6022-9. PubMed ID: 24161572
[TBL] [Abstract][Full Text] [Related]
10. Replacement of in vivo human rabies vaccine potency testing by in vitro glycoprotein quantification using ELISA - Results of an international collaborative study.
Morgeaux S; Poirier B; Ragan CI; Wilkinson D; Arabin U; Guinet-Morlot F; Levis R; Meyer H; Riou P; Shaid S; Volokhov D; Tordo N; Chapsal JM
Vaccine; 2017 Feb; 35(6):966-971. PubMed ID: 28081969
[TBL] [Abstract][Full Text] [Related]
11. Characterization of rabies virus strains used for vaccine production by means of monoclonal antibodies.
Sureau P; Rollin P; Lafon M
Dev Biol Stand; 1984; 57():227-31. PubMed ID: 6084613
[TBL] [Abstract][Full Text] [Related]
12. Engineering of a recombinant trivalent single-chain variable fragment antibody directed against rabies virus glycoprotein G with improved neutralizing potency.
Turki I; Hammami A; Kharmachi H; Mousli M
Mol Immunol; 2014 Feb; 57(2):66-73. PubMed ID: 24091293
[TBL] [Abstract][Full Text] [Related]
13. Rabies vaccine potency control: comparison of ELISA systems for antigenicity testing.
Rooijakkers EJ; Uittenbogaard JP; Groen J; Osterhaus AD
J Virol Methods; 1996 Apr; 58(1-2):111-9. PubMed ID: 8783156
[TBL] [Abstract][Full Text] [Related]
14. Fusion Peptide Improves Stability and Bioactivity of Single Chain Antibody against Rabies Virus.
Xi H; Zhang K; Yin Y; Gu T; Sun Q; Shi L; Zhang R; Jiang C; Kong W; Wu Y
J Microbiol Biotechnol; 2017 Apr; 27(4):718-724. PubMed ID: 28068664
[TBL] [Abstract][Full Text] [Related]
15. An electrochemiluminescence assay for analysis of rabies virus glycoprotein content in rabies vaccines.
Smith TG; Ellison JA; Ma X; Kuzmina N; Carson WC; Rupprecht CE
Vaccine; 2013 Jul; 31(33):3333-8. PubMed ID: 23742991
[TBL] [Abstract][Full Text] [Related]
16. Standardization of an enzyme immunoassay for the in vitro potency assay of inactivated tissue culture rabies vaccines: determination of the rabies virus glycoprotein with polyclonal antisera.
Thraenhart O; Ramakrishnan K
J Biol Stand; 1989 Oct; 17(4):291-309. PubMed ID: 2613705
[TBL] [Abstract][Full Text] [Related]
17. In vitro potency tests: challenges encountered during method development.
Yomayuza CL; Thiel HJ; König M
Dev Biol (Basel); 2012; 134():93-100. PubMed ID: 22888600
[TBL] [Abstract][Full Text] [Related]
18. A DNA vaccine that encodes rabies virus glycoprotein lacking transmembrane domain enhances antibody response but not protection.
Gupta PK; Sharma S; Walunj SS; Patil AA; Rai A; Saini M
Acta Virol; 2006; 50(2):87-92. PubMed ID: 16808325
[TBL] [Abstract][Full Text] [Related]
19. The effect of strain differences on the assay of rabies virus glycoprotein by single radial immunodiffusion.
Ferguson M; Wachmann B; Needy CF; Fitzgerald EA
J Biol Stand; 1987 Jan; 15(1):73-7. PubMed ID: 3104342
[TBL] [Abstract][Full Text] [Related]
20. Effect of the contents and form of rabies glycoprotein on the potency of rabies vaccination in cattle.
Piza AT; Pieri KM; Lusa GM; Caporale GM; Terreran MT; Machado LA; Zanetti CR
Mem Inst Oswaldo Cruz; 2002 Mar; 97(2):265-8. PubMed ID: 12016455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
